Frontiers in Pharmacology
Cure8 research brief
Why This Matters
The study identifies a potential new mechanism—blocking ferroptosis via CA9—for reducing intestinal inflammation in a mouse model, which could guide future IBD drug research.
Who Should Pay Attention
Researchers (ferroptosis, CA9, drug discovery), translational scientists, clinicians following preclinical IBD research
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The paper describes experiments in mice and cultured Caco-2 cells showing that ATT-I improved colon histology, lowered inflammatory cytokines, and modulated ferroptosis markers (GPX4, SLC7A11, COX-2, ACSL4).
Chemical-protein interaction work (docking and CETSA) points to CA9 as a binding target, and AAV9-mediated knockdown of CA9 removed ATT-I's protective effects, supporting CA9’s role in the mechanism. The findings are preclinical: they come from a DSS-induced colitis mouse model and cell lines, not from human studies.
That means ATT-I is a candidate for further research but not an established or approved IBD treatment.
Keep In Mind
Findings are from DSS-induced colitis in mice and Caco-2 cell experiments; human relevance, clinical safety, and efficacy remain to be established.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFrontiers in Pharmacology
PublisherFrontiers Media SA
AuthorsYan Wang, Min Liang, Hanqing Guo +4 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 27, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Callistephus A from Callistephus chinensis Alleviates DSS-Induced Ulcerative Colitis and Gut-liver Axis Disruption by Targeting the JAK2/STAT1 Pathway and Remodeling Gut Microbiota.
The study identifies a plant-derived compound that reduced inflammation and liver injury in a mouse model of ulcerative colitis and ties its effects to both JAK2/STAT1 inhibition and changes in the gut microbiota—two...
Arctigenin, a Lignan Ingredient in Burdock, Inhibits Gasdermin D-Mediated Pyroptosis of Colonic Macrophages to Alleviate Ulcerative Colitis by Down-Regulating Fatty Acid Oxidation.
The study identifies a cellular mechanism by which arctigenin reduced inflammatory macrophage death and improved colitis in mice, suggesting a potential new target (macrophage FAO → GSDMD) for therapies or...
Mycobacterium tuberculosis PPE2 protein-derived peptide ameliorates DSS-induced colitis by depleting mast cells
This mouse study identifies a novel peptide that reduced DSS-induced colitis and points to mast cells and fibroblast–mast cell interactions as potential therapeutic targets. It also showed additive benefit when combined...